Cargando…

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

Increasing rates of antimicrobial resistance among strains of Streptococcus, Staphylococcus, and Enterococcus spp. have been widely documented. At least 50% of nosocomial Staphylococcus aureus infections in intensive care units in the US and UK are due methicillin-resistant S. aureus (MRSA). Drug re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bennett, Jason W, Lewis, James S, Ellis, Michael W
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503664/ https://www.ncbi.nlm.nih.gov/pubmed/18728718

Ejemplares similares

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Meropenem in the treatment of complicated skin and soft tissue infections
por: Fish, Douglas N
Publicado: (2006)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
por: Leuthner, Kimberly D, et al.
Publicado: (2016)

2362. Emergency Department Resource Utilization After Implementation of a Dalbavancin Pathway for Skin and Soft-Tissue Infections
por: Heil, Emily, et al.
Publicado: (2018)

Impact of an Antimicrobial Stewardship and Emergency Department Initiated Dalbavancin Guideline for Patients with Acute Bacterial Skin and Soft-Tissue Infections
por: Burgess, Donna R, et al.
Publicado: (2017)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
por: Juul, Janelle J, et al.
Publicado: (2016)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
por: Buzón-Martín, Luis, et al.
Publicado: (2021)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin
por: White, Beth, et al.
Publicado: (2011)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections
por: Sivori, Francesca, et al.
Publicado: (2022)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections
por: Dimopoulou, Dimitra, et al.
Publicado: (2023)

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections
por: Maraki, Sofia, et al.
Publicado: (2023)

Dalbavancin in Bone and Joint Infections: A Systematic Review
por: Lovatti, Sofia, et al.
Publicado: (2023)

Linezolid in the treatment of HIV-infected patients with complicated skin and soft tissue infections
por: Khachatryan, N, et al.
Publicado: (2007)

Complicated skin, skin structure and soft tissue infections - are we threatened by multi-resistant pathogens?
por: Kujath, P, et al.
Publicado: (2010)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
por: Mpenge, Mbiye A, et al.
Publicado: (2015)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia
por: Esposito, Susanna, et al.
Publicado: (2021)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
por: Stroffolini, Giacomo, et al.
Publicado: (2022)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin
por: Eckmann, Christian, et al.
Publicado: (2010)

Profiling of serum factors associated with Staphylococcus aureus skin and soft tissue infections as a foundation for biomarker identification
por: Bergmann-Leitner, Elke S., et al.
Publicado: (2023)

Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients
por: Pizzuti, Adam G., et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics
por: Leong, Hoe Nam, et al.
Publicado: (2018)

Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
por: Dunn, Christopher J.
Publicado: (2006)

Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial
por: McCarthy, Matthew W., et al.
Publicado: (2019)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections
por: Giorgobiani, Manana, et al.
Publicado: (2022)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

Topical Antiseptic Formulations for Skin and Soft Tissue Infections
por: Hoang, Thi Phuong Nga, et al.
Publicado: (2021)

Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review
por: Cooper, Margaret M, et al.
Publicado: (2021)

2374. Genomic Characteristics of Recurrent Staphylococcus aureus Skin and Soft-Tissue Infection Among US Army Trainees
por: Verratti, Kathleen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q9ldrrv94gbct2ue4c3qq0c0ph